A pharmacoeconomic model to aid in the allocation of ambulatory clinical pharmacy services

Journal of Clinical Pharmacology

Volumn 38, Issue 9, 1998, Pages 783-791

  Lehmann, David F ^a   Medicis, Joseph J ^a  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE;

ADULT; AMBULATORY CARE; ARTICLE; CLINICAL ARTICLE; CLINICAL PHARMACY; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DIAGNOSIS RELATED GROUP; DRUG COST; DRUG UTILIZATION; FEMALE; HEALTH CARE COST; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; MALE; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PRESCRIPTION; QUALITY ADJUSTED LIFE YEAR; RESOURCE ALLOCATION; UTILIZATION REVIEW;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AMBULATORY CARE FACILITIES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY DISEASE; COST ALLOCATION; COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MODELS, ECONOMIC; PHARMACEUTICAL SERVICES; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0031658480     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Weinstein MC, Stason WB: Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977;296: 716-721.
2. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC: The role of cost-effectiveness analysis in health and medicine. JAMA 1996;276:1172-1177.
3. Alexander B, Nasrallah HA, Perry PJ, Liskow BI, Dunner FJ: The impact of psychopharmacology education on prescribing practices. Hosp Community Psychiatry 1983;34:1150-1153.
4. Lobas NH, Lepinski PW, Abramowitz PW: Effects of pharmaceutical care on medication cost and quality of patient care in an ambulatory care clinic. Am J Hosp Pharm 1992;49:1681-1688.
5. Sumpton JE, Frewen TC, Rieder MJ: The effect of physician education on knowledge of drug therapeutics and costs. Ann Pharmacother 1992;26:692-697.
6. Hanlon JT, Andolsek KM, Clapp-Channing NE, Gehlbach SH: Drug prescribing in a family medicine residency program with a pharmacotherapeutics curriculum. J Med Educ 1986;61:64-67.
7. Montazeri M, Cook DJ: Impact of a clinical pharmacist in a multidisciplinary intensive care unit. Crit Care Med 1994; 22:1044-1048.
8. Aucott JN, Pelecanos E, Dombrowski R, Fuehrer SM, Laich J, Aron DC: Implementation of local guidelines for cost-effective management of hypertension. J Gen Intern Med 1996;11:139-146.
9. Siegel JE, Krolewski AS, Warram JH, Weinstein MC: Cost-effectiveness of screening and early treatment of nephropathy in patients with insulin-dependent diabetes mellitus. J Am Soc Nephrol 1992;3(suppl):S111-S119.
10. Goldman L, Sia STB, Cook EF, Rutherford JD, Weinstein MC: Costs and effectiveness of routine therapy with long term beta adrenergic antagonists after acute myocardial infarction. N Engl J Med 1988;319:152-157.
11. Inui TS, Yourtee EL, Williamson JW: Improved outcomes in hypertension after physician tutorials. Ann Intern Med 1976;84: 646-651.
12. Lipton HL, Bird JA: Drug utilization review in ambulatory settings: state of the science and directions for outcomes research. Medical Care 1993;31:1069-1072.
13. Parving HH, Andersen AR, Smidt UM, Svendsen PAA: Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983;2:1175-1179.
14. Goldstein S: Beta blockers in hypertensive and coronary heart disease. Arch Intern Med 1996;156:1267-1276.
15. The Norwegian Multicenter Study Group: Timolol-induced reduction in mortality and reinfarction in patients surviving actute myocardial infarction. N Engl J Med 1981;404:801-807.
16. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327: 685-691.
17. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-1462.
18. Norcross WA: Angiotensin converting enzyme inhibitors in congestive heart failure (letter). Wisconsin J Med 1995;163:67.
19. Gold JA: Improving use of ACE inhibitors in diabetic nephropathy. Wisconsin J Med 1996;67:588-589.
20. Viskin S, Kitzis I, Lev E, Zak Z, Heller K, Villa Y, et al: Treatment with beta adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. J Am Coll Cardiol 1995;25:1327-1332.
21. Brand DA, Newcomer LN, Freiburger A, Tian H: Cardiologist's practices compared with practice guidelines: use of beta blockade after acute myocardial infarction. J Am Coll Cardiol 1995;26:1432-1436.
22. Soumerai SB, McLaughlin TJ, Spiegelman D, Hertzmark E, Thibault G, Goldman L: Adverse outcomes of underuse of beta blockers in elderly survivors of acute myocardial infarction. JAMA 1997;277:115-121.
23. Beck JR, Pauker SG: The Markov process in medical prognosis. Med Decision Making 1983;3:419-458.
24. Sonnenberg FA, Beck JR: Markov models in medical decision making: a practical guide. Med Decision Making 1993;13:322-338.
25. McGovern PG, Pankow JS, Shahar E, Doliszny KM, Folsom AR, Blackburn H, Luepker RV and the Minnesota Heart Survey Investigators: Recent trends in acute coronary heart disease: mortality, morbidity, medical care, and risk factors. N Engl J Med 1996;334:884-890.
26. Tschope W, Koch M, Thomas B, Ritz E: Serum lipids predict cardiac death in diabetic patients on maintenance hemodialysis. Nephron 1993;64:354-358.
27. Rodeheffer RJ, Jacobsen SJ, Gersh BJ, Kottke TE, McCann HA, Bailey KR, Ballard DJ: The incidence and prevalence of congestive heart failure in Rochester, Minnesota. Mayo Clin Proc 1993;68: 1143-1150.
28. Butler JRG, Fletcher PJ: A cost-effectiveness analysis of enalapril maleate in the management of congestive heart failure in Australia. Aust N Z J Med 1996;26:89-95.
29. Health Care Financing Administration: The Medicare DRG Handbook of Comparative Clinical and Financial Standards. Cleveland, OH: Health Care Investment Analysts, 1991.
30. HealthCare Consultants of America: Physicians Fee and Coding Guide. Augusta, GA: HealthCare Consultants of America, 1997.
31. Lipscomb J, Weinstein MC, Torrance GW: Time preference. In, Gold MR, Russell LB, Weinstein MC (eds.): Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
32. Cardinale V (ed.): Drug Topics Red Book. Montvale, NJ: Medical Economics Company, 1997.
33. Chrischilles EA, Helling DK, Rowland CR: Clinical pharmacy services in family practice: physical time and quality of care. Drug Intell Clin Pharm 1984;18:333-341.
34. Dong BJ, Echaves SA, Brody RV, Shapiro DW: Pharmacist provision of preventive health services in a hypertension clinic. Am J Health Systems Pharm 1997;54:564-566.
35. Canadian Erythropoietin Study Group: Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Br Med J 1990; 300:573-578.
36. Tsevat J, Goldman L, Soukup JR, Lamas GA, Connors KF, Chapin CC, Lee TH: Stability of time-tradeoff utilities in survivors of myocardial infarction. Med Decision Making 1993;13:161-165.
37. Stewart AL, Greenfield S, Hays RD, Wells K, Rogers WH, Berry SD, et al: Functional status and well-being of patients with chronic conditions: results from the Medical Outcomes study. JAMA 1989;262:907-913.
38. Laupacis A, Feeny D, Detsky AS, Tugwell PX: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluation. Can Med Assoc J 1992;146:473-481.
39. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB: Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-1258.
40. Pitt B: Angiotensin-converting enzyme inhibitors in patients with coronary atherosclerosis. Am Heart J 1994;128:1328-1332.
41. Rogers WJ, Johnstone DE, Yusuf S, Weiner DH, Gallagher P, Bittner VA, et al: Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: the studies of left ventricular dysfunction. J Am Coll Cardiol 1994;23:393-400.
42. Audet AM, Greenfield S, Field M: Medical practice guidelines: current activities and future directions. Ann Intern Med 1990;113:709-714.
43. Wilson MC, Tunis SR, Hayward RS, Kern DE, Howard DM, Bass EB: Primary care physicians attitudes toward clinical practice guidelines. Med Decision Making 1991;11:334.
44. Greco PJ, Eisenberg JM: Changing physicians practices. N Engl J Med 1993;1271-1274.
45. Kelly HW: Asthma pharmacotherapy: current practices and outlook. Pharmacotherapy 1997;17:13S-21S.
46. Fraser WD: Bone preservation and the menopause. Br J Hosp Med 1997;57:212-214.